Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
DDI Study of Fostemsavir with Methadone or Buprenorphine/Naloxone
NCT02666001Phase 1Completed
- Sponsor
- ViiV Healthcare
- Start
- Jan 2016
- Primary completion
- Jun 2016
- Modality
- Small Molecules
- Countries
- 1
01
Overview
Phase 1, open-label trial of fostemsavir in human immunodeficiency virus type 1 infection (HIV-1) (2 arms), sponsored by ViiV Healthcare. Primary endpoints: Maximum Observed Plasma Concentration (Cmax) for Methadone, Area Under the Concentration-Time Curve Over a Dosing Interval (AUC(TAU)) for Methadone and 4 more. Started Jan 2016; status: completed.
02
Drugs
fostemsavir
03
Conditions
human immunodeficiency virus type 1 infection (HIV-1)
Beyond the preview
Go deeper on NCT02666001.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT02666001.